Erratum: FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders (Proceedings of the National Academy of Sciences of the United States of America (2011), 108, (E1339-E1348) DOI: 10.1073/pnas.1102349108);FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 49, 2011, Pages 21282-

  Kiyota, Tomomi ^a   Ingraham, Kaitlin L ^b   Jacobsen, Michael T ^a   Xiong, Huangui ^a   Ikezu, Tsuneya ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblast growth factor; Neurodegenerative disorders; Transgenic mouse model; Viral gene therapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BROXURIDINE; DOUBLECORTIN; FIBROBLAST GROWTH FACTOR 2; NEURON SPECIFIC NUCLEAR PROTEIN; OLIGOMER; PRESENILIN 1; PROTEIN C FOS;

ADENOVIRUS; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CELL DIFFERENTIATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DENTATE GYRUS; GENE TARGETING; GENE TRANSFER; HIPPOCAMPUS; LEARNING; MAZE TEST; MICROGLIA; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROCOGNITIVE DISORDER; NEUROPATHOLOGY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 83755183710     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1119280109     Document Type: Erratum

References (72)

1. Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340:1970-1980.
2. Forman MS, Trojanowski JQ, Lee VM (2004) Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10:1055-1063. (Pubitemid 39424865)
3. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791.
4. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
5. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403. (Pubitemid 44108123)
6. Schenk D, et al. (1999) Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature 400:173-177. (Pubitemid 29327547)
7. Morgan D, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985. (Pubitemid 32101645)
8. Bard F, et al. (2003) Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028. (Pubitemid 36254567)
9. Hock C, et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554. (Pubitemid 36645030)
10. Birmingham K, Frantz S (2002) Set back to Alzheimer vaccine studies. NatMed 8:199-200. (Pubitemid 34250084)
11. Check E (2002) Nerve inflammation halts trial for Alzheimer's drug. Nature 415:462.
12. Carlson C, et al. (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7:396-401.
13. Imbimbo BP, Giardina GA (2011) γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: Disappointments and hopes. Curr Top Med Chem 11:1555-1570.
14. Tuszynski MH, et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551-555. (Pubitemid 40691288)
15. Nagahara AH, et al. (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15:331-337.
16. Bishop KM, et al. (2008) Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol 211:574-584.
17. Wu K, et al. (2005) AAV2/5-mediated NGF gene delivery protects septal cholinergic neurons following axotomy. Brain Res 1061:107-113. (Pubitemid 41587918)
18. Mudò G, et al. (2009) The FGF-2/FGFRs neurotrophic system promotes neurogenesis in the adult brain. J Neural Transm 116:995-1005.
19. Jin K, et al. (2003) Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell 2:175-183.
20. Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH (1997) Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci 17:5820-5829. (Pubitemid 27310497)
21. Tao Y, Black IB, DiCicco-Bloom E (1997) In vivo neurogenesis is inhibited by neutralizing antibodies to basic fibroblast growth factor. J Neurobiol 33:289-296. (Pubitemid 27360499)
22. Baldauf K, Reymann KG (2005) Influence of EGF/bFGF treatment on proliferation, early neurogenesis and infarct volume after transient focal ischemia. Brain Res 1056:158-167. (Pubitemid 41557703)
23. Sapieha PS, Peltier M, Rendahl KG, Manning WC, Di Polo A (2003) Fibroblast growth factor-2 gene delivery stimulates axon growth by adult retinal ganglion cells after acute optic nerve injury. Mol Cell Neurosci 24:656-672. (Pubitemid 37506010)
24. Schuettauf F, et al. (2004) Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity. Curr Eye Res 29:379-386. (Pubitemid 40138377)
25. Chen K, Henry RA, Hughes SM, Connor B (2007) Creating a neurogenic environment: The role of BDNF and FGF2. Mol Cell Neurosci 36:108-120. (Pubitemid 47379558)
26. Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I (2007) Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 28:1148-1162. (Pubitemid 46810057)
27. Cummings BJ, Su JH, Cotman CW (1993) Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. Exp Neurol 124:315-325. (Pubitemid 24041779)
28. Kiyota T, et al. (2010) CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J 24:3093-3102.
29. Kiyota T, et al. (2011) AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther, 10.1038/gt.2011.126.
30. Kiyota T, et al. (2009) AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther 17:803-809.
31. Wilcock DM, et al. (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24.
32. Wagner JP, Black IB, DiCicco-Bloom E (1999) Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor. J Neurosci 19:6006-6016. (Pubitemid 29327934)
33. Rao MS, Shetty AK (2004) Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. Eur J Neurosci 19:234-246. (Pubitemid 38177862)
34. Abraham WC, et al. (1993) Correlations between immediate early gene induction and the persistence of long-term potentiation. Neuroscience 56:717-727. (Pubitemid 23290584)
35. Worley PF, et al. (1993) Thresholds for synaptic activation of transcription factors in hippocampus: correlation with long-term enhancement. J Neurosci 13:4776-4786. (Pubitemid 23326347)
36. Seeds NW, Williams BL, Bickford PC (1995) Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 270:1992-1994. (Pubitemid 26097189)
37. Vann SD, Brown MW, Aggleton JP (2000) Fos expression in the rostral thalamic nuclei and associated cortical regions in response to different spatial memory tests. Neuroscience 101:983-991.
38. Robertson HA (1992) Immediate-early genes, neuronal plasticity, and memory. Biochem Cell Biol 70:729-737.
39. Dragunow M (1996) A role for immediate-early transcription factors in learning and memory. Behav Genet 26:293-299.
40. Malenka RC, Bear MF (2004) LTP and LTD: An embarrassment of riches. Neuron 44:5-21. (Pubitemid 39348827)
41. Saganich MJ, et al. (2006) Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci 26:13428-13436. (Pubitemid 46026474)
42. Kiyota T, et al. (2009) CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE 4:e6197.
43. Hsiao K, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102. (Pubitemid 26332733)
44. Martin BK, et al.; ADAPT Research Group (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896-905. (Pubitemid 352008472)
45. Shors TJ, et al. (2001) Neurogenesis in the adult is involved in the formation of trace memories. Nature 410:372-376. (Pubitemid 32246054)
46. Aimone JB, Wiles J, Gage FH (2009) Computational influence of adult neurogenesis on memory encoding. Neuron 61:187-202.
47. Yamasaki TR, et al. (2007) Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 27:11925-11933. (Pubitemid 350072121)
48. Donovan MH, et al. (2006) Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 495:70-83. (Pubitemid 43238052)
49. Feng R, et al. (2001) Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 32:911-926. (Pubitemid 34024850)
50. Haughey NJ, et al. (2002) Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 83:1509-1524. (Pubitemid 35477489)
51. Wen PH, et al. (2004) The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol 188:224-237. (Pubitemid 38891583)
52. Jin K, et al. (2004) Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci USA 101:13363-13367. (Pubitemid 39209671)
53. Wang JM, et al. (2010) Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 107:6498-6503.
54. Magnus T, Chan A, Savill J, Toyka KV, Gold R (2002) Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 130:1-9. (Pubitemid 35239988)
55. Waldau B, Shetty AK (2008) Behavior of neural stem cells in the Alzheimer brain. Cell Mol Life Sci 65:2372-2384.
56. Qian X, Davis AA, Goderie SK, Temple S (1997) FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron 18:81-93. (Pubitemid 27053832)
57. Stachowiak MK, Maher PA, Joy A, Mordechai E, Stachowiak EK (1996) Nuclear localization of functional FGF receptor 1 in human astrocytes suggests a novel mechanism for growth factor action. Brain Res Mol Brain Res 38:161-165. (Pubitemid 26159205)
58. Stachowiak MK, Maher PA, Stachowiak EK (2007) Integrative nuclear signaling in cell development - a role for FGF receptor-1. DNA Cell Biol 26:811-826. (Pubitemid 350274413)
59. Dunham-Ems SM, et al. (2009) Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. Mol Biol Cell 20:2401-2412.
60. Stachowiak EK, Fang X, Myers J, Dunham S, Stachowiak MK (2003) cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1). J Neurochem 84:1296-1312. (Pubitemid 36343596)
61. Duff K, et al. (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713. (Pubitemid 26360645)
62. Klein RL, et al. (2002) Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain. Methods 28:286-292. (Pubitemid 35341093)
63. Xiao W, et al. (1999) Gene therapy vectors based on adeno-associated virus type 1. J Virol 73:3994-4003. (Pubitemid 29189844)
64. Xiao X, Li J, McCown TJ, Samulski RJ (1997) Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 144:113-124. (Pubitemid 27149611)
65. Yamamoto M, et al. (2005) Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol 166:1475-1485. (Pubitemid 40586517)
66. Yamamoto M, et al. (2007) Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170:680-692. (Pubitemid 47339404)
67. Anderson ER, et al. (2003) Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neuroscience 118:359-369. (Pubitemid 36423251)
68. Anderson ER, Gendelman HE, Xiong H (2004) Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci 24:7194-7198. (Pubitemid 39096385)
69. Sato S, et al. (2008) Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tautubulin kinase 1. J Neurosci 28:14511-14521.
70. Lan X, et al. (2011) HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes. J Immunol 186:6925-6932.
71. Xu J, et al. (2010) Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity. J Neurochem 116:192-204.
72. Tokuraku K, Marquardt M, Ikezu T (2009) Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes. PLoS ONE 4:e8492.